<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug</th>
<th>Applicant</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 019292</td>
<td>MD–76R (diatrizoate meglumine and diatrizoate sodium) Injection, 66%/10%.</td>
<td>Liebel-Flarsheim Co. LLC.</td>
</tr>
<tr>
<td>NDA 020014</td>
<td>Maxair Autohaler (pirbuterol acetate inhalation aerosol), EQ 0.2 mg base/inhalation.</td>
<td>Bausch Health US, LLC.</td>
</tr>
<tr>
<td>NDA 021041</td>
<td>DepoCyt (cytarabine liposome) Injection, 10 mg/mL</td>
<td>Pacira Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>NDA 021338</td>
<td>Ionsys (fentanyl iontophoresis transdermal system), 40 mcg/activation.</td>
<td>Merck Sharp &amp; Dohme Corp.</td>
</tr>
<tr>
<td>NDA 021575</td>
<td>Fosamax (alendronate sodium) Oral Solution, EQ 70 mg base/75 mL.</td>
<td>Allergan Sales, LLC,</td>
</tr>
<tr>
<td>NDA 022222</td>
<td>Ultresa (pancrelipase (amylase, lipase, protease)), Delayed-Release Capsules, 8,000 USP Units/4,000 USPUnits/8,000 USP Units/27,600 USP Units/13,800 USP Units/20,700 USP Units/41,400 USP Units, and 46,000 USP Units/23,000 USP Units/46,000 USP Units.</td>
<td>Merck Sharp &amp; Dohme Corp., 1 Merck Dr., P.O. Box 100, Whitehouse Station, NJ 08889–0100.</td>
</tr>
<tr>
<td>NDA 022396</td>
<td>Dylloject (diclofenac sodium) Injection, 37.5 mg/mL</td>
<td>Allergan Sales, LLC,</td>
</tr>
<tr>
<td>NDA 023568</td>
<td>Kynamro ( mipomersen sodium) Injection, 200 mg/mL</td>
<td>Javelin Pharmaceuticals, Inc.,</td>
</tr>
</tbody>
</table>

Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of August 2, 2019. Approval of each entire application is withdrawn, including any strengths or products inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on August 2, 2019 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

Dated: June 28, 2019.
Lowell J. Schiller,  
Principal Associate Commissioner for Policy.

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Food and Drug Administration  
[Docket No. FDA–2019–P–1366]  

Determination That CLAFORAN (Cefotaxime Sodium) for Injection, 500 Milligrams/Vial, 1 Gram/Vial, 2 Grams/Vial and 10 Grams/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness  

AGENCY: Food and Drug Administration, HHS.  
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) has determined that CLAFORAN (cefotaxime sodium) for injection, 500 milligrams (mg)/vial, 1 gram (g)/vial, 2 g/vial and 10 g/vial, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.


SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products under an ANDA procedure. ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is known generally as the “Orange Book.” Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug’s NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

CLAFORAN (cefotaxime sodium) for injection, 500 mg/vial, 1 g/vial, 2 g/vial and 10 g/vial, is the subject of NDA 050547, held by US Pharmaceutical Holdings II LLC, and initially approved on March 11, 1981. CLAFORAN is indicated for the treatment of patients with serious bacterial infections in eight different organ systems caused by susceptible strains of microorganisms, as specified in the labeling.

In a letter dated February 9, 2018, US Pharmaceutical Holdings II LLC notified FDA that CLAFORAN (cefotaxime for injection) 500 mg/vial, 1 g/vial, 2 g/vial and 10 g/vial was being discontinued, and FDA moved the drug product to the “Discontinued Drug Product List” section of the Orange Book.
Cardinal Health Regulatory Sciences submitted a citizen petition dated January 31, 2019 (Docket No. FDA–2019–P–1366), under 21 CFR 10.30, requesting that the Agency determine whether CLAFORAN (cefotaxime sodium) for injection, 500 mg/vial, 1 g/vial, 2 g/vial and 10 g/vial was withdrawn from sale for reasons of safety or effectiveness.

After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that CLAFORAN (cefotaxime sodium) for injection, 500 mg/vial, 1 g/vial, 2 g/vial and 10 g/vial was not withdrawn for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that CLAFORAN (cefotaxime sodium) for injection, 500 mg/vial, 1 g/vial, 2 g/vial and 10 g/vial was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of CLAFORAN (cefotaxime sodium) for injection, 500 mg/vial, 1 g/vial, 2 g/vial and 10 g/vial from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list CLAFORAN (cefotaxime sodium) for injection, 500 mg/vial, 1 g/vial, 2 g/vial and 10 g/vial in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. FDA will not begin procedures to withdraw approval of approved ANDAs that refer to this drug product. Additional ANDAs for this drug product may also be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Dated: June 27, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.

[FR Doc. 2019–14172 Filed 7–2–19; 8:45 am]
BILLING CODE 4164–01–P